Showing 2421-2430 of 5644 results for "".
- NovaBay Pharmaceuticals Partners with Harrow Health’s ImprimisRx to Promote Prescription Avenovahttps://modernod.com/news/novabay-pharmaceuticals-partners-with-harrow-healths-imprimisrx-to-promote-prescription-avenova/2479378/NovaBay Pharmaceuticals announced it has partnered with ImprimisRx to promote prescription Avenova. ImprimisRx, a wholly owned subsidiary of Harrow Health, will provide NovaBay with national sales, marketing, and distribution support for its FDA-cleared 0.01% hypochlorous acid Avenova in 40 ml bo
- FDA Grants Alkeus Pharmaceuticals Breakthrough Therapy Designation for ALK-001 for the Treatment of Stargardt Diseasehttps://modernod.com/news/fda-grants-alkeus-pharmaceuticals-breakthrough-therapy-designation-for-alk-001-c20-d3-vitamin-a-for-the-treatment-of-stargardt-disease/2479374/Alkeus Pharmaceuticals announced that the FDA has granted Breakthrough Therapy Designation to ALK-001 for the treatment of Stargardt Disease. ALK-001 (C20-D3-vitamin A) is a chemically-modified form of vitamin A developed to treat multiple retinal degenerati
- Opthea’s OPT-302 Granted FDA Fast Track Designation for Wet AMDhttps://modernod.com/news/optheas-opt-302-granted-fda-fast-track-designation-for-wet-amd/2479360/Opthea has announced FDA has granted Fast Track designation for the company’s VEGF-C/-D ‘trap’ inhibitor, OPT-302, in combination with anti-VEGF-A therapy for the treatment of patients with wet age-related macular degeneration (AMD). The FDA’s Fast Track pro
- Horizon Therapeutics Partners With Olympic Gold Medalist Gail Devers to Raise Awareness of Graves’ Disease and Symptoms of Thyroid Eye Disease (TED)https://modernod.com/news/horizon-therapeutics-partners-with-olympic-goldmmedalist-gail-devers-to-raise-awareness-of-graves-disease-and-symptoms-of-thyroid-eye-disease-ted/2479357/For Graves’ Disease Awareness Month in July, Horizon Therapeutics is teaming up with track star and three-time Olympic gold medalist Gail Devers, who has been living with Graves’ disease and symptoms of Thyroid Eye Disease (TED) for more than 30 years. Horizon and Ms. Devers are collaborating wit
- Mikajaki Partners With Segula Technologies to Develop Ophthalmic Diagnosis Devicehttps://modernod.com/news/mikajaki-partners-with-segula-technologies-to-develop-ophthalmic-diagnosis-device/2479353/Swiss startup Mikajaki is teaming up with engineering group Segula Technologies to develop the first operational series of EyeLib, an automated diagnostic station that aims to revolutionize the management of the growing number of patients with vision disorders, according to a company news release
- ASCRS: Insurance Company Policy Delays Sight-Restoring Surgery, Puts Patients in Jeopardyhttps://modernod.com/news/ascrs-insurance-company-policy-delays-sight-restoring-surgery-puts-patients-in-jeopardy/2479334/The decision by Aetna to require preauthorization of all cataract surgery procedures went into effect July 1. In a news release, ASCRS said it is opposed to the preauthorization policy, stating it will create delays i
- Nicox’s NCX 470 Demonstrates Significant Intraocular Pressure Lowering in Dolomites Phase 2 Glaucoma Trialhttps://modernod.com/news/nicoxs-ncx-470-demonstrates-significant-intraocular-pressure-lowering-in-dolomites-phase-2-glaucoma-trial/2479333/Nicox presented results from the Dolomites phase 2 clinical trial showing that NCX 470, a novel nitric oxide (NO)-donating prostaglandin analog (PGA), produced significantly greater IOP lowering effects in glaucoma patients compared with the current standard of care, latanoprost. In Dolom
- FDA Accepts Application for Genentech’s Port Delivery System with Ranibizumab (PDS) for Treatment of Wet AMDhttps://modernod.com/news/fda-accepts-application-for-genentechs-port-delivery-system-with-ranibizumab-pds-for-treatment-of-wet-amd/2479322/Genentech announced that the FDA has accepted the company’s Biologics License Application (BLA), under Priority Review, for Port Delivery System with ranibizumab (PDS) for the treatment of wet age-related macular degeneration (AMD). If approved, PDS would be a first-of-its-kind therapeutic approa
- Gyroscope Announces Research Collaboration with CMRI to Develop Gene Therapy Capsidshttps://modernod.com/news/gyroscope-announces-research-collaboration-with-cmri-to-develop-gene-therapy-capsids/2479315/Gyroscope Therapeutics announced the company has entered a research collaboration with Children’s Medical Research Institute (CMRI) in Australia to develop next-generation clinical capsids, the protein shells of viral vectors used to deliver gene therapies. A team of researchers from CMRI
- Lenz Therapeutics Debuts with $47 Million Series A Financinghttps://modernod.com/news/lenz-therapeutics-debuts-with-47-million-series-a-financing/2479301/Lenz Therapeutics debuted today with a $47 million Series A financing to move the company’s lead asset, an eyedrop formulation of aceclidine, toward an NDA submission for the treatment of presbyopia. The financing was